## 3 Results
### Secondary Endpoints  
Table 4 presents the results of the descriptive and comparative statistics of secondary endpoint measures across the period of interest. No statistically significant changes were observed in any measure.  
In 2020, we observed a 53% decrease in the number of neurologic counsels per subject. In addition, the rate of subjects receiving at least one rehabilitation cycle per year dropped from 87% (in 2018 and 2019) to 29% in 2020 (Chi-square = 20; \(p<0.0001\)), rising again to 42% in 2021.  
\begin{table}
\begin{tabular}{p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt}} \hline \hline
**Parameter** & **2018** & **2019** & **2020** & **2021** & **Wilcoxon Rank Test (2018 vs. 2019)** & **Wilcoxon Rank Test (2019 vs. 2020)** & **Wilcoxon Rank Test (2020 vs. 2021)** \\ \hline BMI & \(26.3\pm 4.9\) & \(25.9\pm 4.5\) & \(25.8\pm 4.8\) & \(25.9\pm 5.3\) & \(-2.4\,p=0.01\) & \(-0.76\,p=0.44\) & \(-1.58\,p=0.11\) \\ Mean \(\pm\) SD [median; IQR] & \(3.30\pm 3.2\) & \(2.63\pm 2.8\) & \(3.06\pm 3.0\) & \(2.93\pm 3.1\) & \(-1.8\,p=0.06\) & \(-2.5\,p=0.009\) & \(-0.4\,p=0.67\) \\ \([\)median; IQR] & \([3;5]\) & \([2;4]\) & \([3;5]\) & \([2;5]\) & \(-1.8\,p=0.06\) & \(-2.5\,p=0.009\) & \(-0.4\,p=0.67\) \\ \hline LEDD & \(689.7\pm 374.7\) & \(701.9\pm 436.4\) & \(668.1\pm 383.4\) & \(661.7\pm 414.0\) & \(0.34\,p=0.73\) & \(1.5\,p=0.12\) & \(0.0\,p>0.99\) \\ \([\)median; IQR] & \([650;464.3]\) & \([606.5;411.0]\) & \([562,471.5]\) & \([560;472.7]\) & \(0.34\,p=0.73\) & \(1.5\,p=0.12\) & \(0.0\,p>0.99\) \\ \hline \hline \end{tabular}
\end{table}
Table 4: Values of the secondary outcome measures (BMI, UPDRS IV, and LevoDopa Equivalent Daily Doses (LEDDs)) in the period of interest. Comparisons between measures taken in two consecutive years are presented. No statistically significant changes were observed over time.  
\begin{table}
\begin{tabular}{p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt} p{42.7 pt}} \hline \hline \multicolumn{6}{c}{**Dependent Variable**} \\ \hline
**Independent Variable** & **UPDRS II \% Change 2018–2019** & **UPDRS III \% Change 2018–2019** & **NMSS \% Change 2018–2019** & **UPDRS II 2020–2021** & **UPDRS III \% Change 2020–Looking for factors explaining the variance of UPDRS II % change in 2019-2020, we considered patients who received rehabilitation in 2020. The U-Mann-Whitney was applied for this post-hoc comparison between a group of 64 patients who had undergone at least one cycle of rehabilitation sessions (mean UPDRS II change 2019-2020: 0.7% \(\pm\) 26.4 [median \(-\)2.6; IQR 27.8] and the remaining 157 who had not received any training (mean UPDRS II change 2019-2020: 24.7% \(\pm\) 57.5 [median 11.1; IQR 39.3]. The comparison by the U-Mann-Whitney test did not show any significant difference though, just a trend towards a different disability progression in the two subgroups (Z = \(-\)1.9; \(p\) = 0.04).  
Eleven patients with PD (5% of the study sample) developed a SARS-CoV-2 infection in the period of interest. Four subjects died: of them, three were in the advanced stage of disease with comorbidities (diabetes mellitus, cerebral vasculopathy, blood hypertension), and one was in a moderate stage without comorbidity. Among the seven survivors, two suffered from bilateral interstitial pneumonia and were hospitalized and recovered completely, while five subjects suffered from a mild infection without the need for hospitalization. The survivors did not show a significant worsening in either UPDRS or NMSS scores compared to the premorbid condition.